Esophageal cancer: Risk factors, genetic association, and treatment
Article Properties
-
LanguageEnglish
-
DOI (url)
-
Publication Date2018/05/01
-
Journal
-
Indian UGC (journal)
-
Refrences70
-
Citations443
-
Fang-Liang Huang
-
Sheng-Jie Yu
Cite
Huang, Fang-Liang, and Sheng-Jie Yu. “Esophageal Cancer: Risk Factors, Genetic Association, and Treatment”. Asian Journal of Surgery, vol. 41, no. 3, 2018, pp. 210-5, https://doi.org/10.1016/j.asjsur.2016.10.005.
Huang, F.-L., & Yu, S.-J. (2018). Esophageal cancer: Risk factors, genetic association, and treatment. Asian Journal of Surgery, 41(3), 210-215. https://doi.org/10.1016/j.asjsur.2016.10.005
Huang, Fang-Liang, and Sheng-Jie Yu. “Esophageal Cancer: Risk Factors, Genetic Association, and Treatment”. Asian Journal of Surgery 41, no. 3 (2018): 210-15. https://doi.org/10.1016/j.asjsur.2016.10.005.
Huang FL, Yu SJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian Journal of Surgery. 2018;41(3):210-5.
Journal Categories
Medicine
Medicine (General)
Medicine
Surgery
You May Also Like
- Depression and postoperative complications: an overview
- Predictors of surgical site infections among patients undergoing major surgery at Bugando Medical Centre in Northwestern Tanzania
- Minimally invasive 'step-up approach' versus maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN13975868]
- Efficacy of Low Level Laser Therapy on Wound Healing in Patients with Chronic Diabetic Foot Ulcers—A Randomised Control Trial
- Preoperative prediction of difficult lap chole: a scoring method
Refrences
| Title | Journal | Journal Categories | Citations | Publication Date |
|---|---|---|---|---|
| miR-221 mediates chemoresistance of esophageal adenocarcinoma by direct targeting of DKK2 expression | Annals of Surgery |
| 2016 | |
Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial | Cancer Science |
| 31 | 2016 |
| Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis | The Annals of Thoracic Surgery |
| 10 | 2016 |
| Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma | Journal of Gastrointestinal Surgery |
| 28 | 2016 |
| Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma | Oncotarget | 22 | 2016 |
Refrences Analysis
The category
Medicine: Medicine (General) 46
is the most frequently represented among the references in this article. It primarily includes studies from Gastroenterology and The Annals of Thoracic Surgery. The chart below illustrates the number of referenced publications per year.
Refrences used by this article by year
Citations
Citations Analysis
The category
Medicine: Medicine (General) 240
is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer and was published in 2017. The most recent citation comes from a 2024 study titled Exosomal NAT10 from esophageal squamous cell carcinoma cells modulates macrophage lipid metabolism and polarization through ac4C modification of FASN. This article reached its peak citation in 2022, with 133 citations. It has been cited in 252 different journals, 28% of which are open access. Among related journals, the Frontiers in Oncology cited this research the most, with 22 citations. The chart below illustrates the annual citation trends for this article.